首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1593450

個人化醫療市場規模、佔有率、成長分析，按產品、按應用、按最終用戶、按地區 - 產業預測，2024-2031年

Personalized Medicines Market Size, Share, Growth Analysis, By Product, By Application, By End Users, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月09日 | 出版商:

SkyQuest | 英文 209 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球個人化醫療市場規模將為5,120億美元，從2023年的5,703.7億美元成長到2031年的1,3528.1億美元，預計在預測期內（2024-2031年）年複合成長率為11.40%。

全球個人化醫療市場是由基因技術整合所驅動的，目的是為個別患者提供量身定做的治療。由於每個人類基因組都是獨特的，個人化醫療目的是提供特定的診斷和治療，特別是針對癌症。雖然腫瘤學仍然是主要關注點，但遺傳技術的日益普及也刺激了對非腫瘤學應用的需求。基因技術經歷兩位數的成長，投資的增加推動進步。這為個人化醫療治療阿茲海默症和帕金森氏症等罕見疾病創造了新的可能性。儘管醫療保健領域的採用歷來進展緩慢，但醫療保健預算的增加以及製藥公司與政府機構之間合作的加強預計將在未來幾年加速個性化醫療的採用。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Roche Holding AG（Switzerland）
Bristol-Myers Squibb Company（USA）
AstraZeneca PLC（United Kingdom）
Gilead Sciences, Inc.（USA）
Amgen Inc.（USA）
Siemens Healthineers（Germany）
Guardant Health, Inc.（USA）
Exact Sciences Corporation（USA）
EMD Serono, Inc.（USA）
Bio-Rad Laboratories, Inc.（USA）
QIAGEN NV（Netherlands）
Myriad Genetics, Inc.（USA）
AbbVie Inc.（USA）
Takeda Pharmaceutical Company（Japan）
Caris Life Sciences, Inc.（US）
MDxHealth SA（Belgium）
Personalis, Inc.（US）
Freenome Holdings, Inc.（US）
Haplogen, Inc.（US）
Molecular Partners AG（Switzerland）
SOPHiA GENETICS SA（Switzerland）
NantHealth, Inc.（US）
Zymeworks Inc.（Canada）
Celerion（US）

簡介目錄

Product Code: SQMIG35H2307

Global Personalized Medicine Market size was valued at USD 512 billion in 2022 and is poised to grow from USD 570.37 billion in 2023 to USD 1352.81 billion by 2031, growing at a CAGR of 11.40% during the forecast period (2024-2031).

The global Personalized Medicines Market is driven by the integration of genetic technology to deliver tailored treatments for individual patients. As each human genome is unique, personalized medicine aims to provide specific diagnoses and treatments, particularly for cancer. While oncology remains a major focus, the rising availability of genetic technology is spurring demand for non-oncology applications as well. Genetic technology is experiencing double-digit growth, with increasing investment propelling advancements. This has opened new possibilities for personalized medicine in treating rare diseases, including Alzheimer's and Parkinson's. Despite the historically slow adoption in healthcare, growing healthcare budgets and increased collaborations between pharmaceutical companies and government agencies are expected to accelerate the adoption of personalized medicine in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Personalized Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Personalized Medicine Market Segmental Analysis

Global Personalized Medicine Market is segmented by Product, Application, End Users, and region. Based on Product, the market is segmented into Personalized Medicine Testing (Genetic Testing, DTC Testing, Others), Personalized Medicine Therapeutics (Pharmaceuticals, Medical Devices, Others), Personalized Medical Care (Telemedicine, Health Information Technology), Personalized Nutrition & Wellness (Retail Nutrition, Complementary & Alternative Medicine). Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Antiviral, Psychiatry, Immunology, and Others. Based on End Users, the market is segmented into Hospitals And Clinical Care, Diagnostic Companies and Testing Facilities, Academic Research Institutes and Research Laboratories, Contract Research Organizations, Bio and Health Informatics Companies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Personalized Medicine Market

The rapid advancement of genetic technology is significantly influencing the healthcare and pharmaceutical industries, driving the demand for personalized medicines. With the genetic technology market valued at over USD 5 billion and anticipated to grow at a compound annual growth rate (CAGR) of more than 20% throughout the forecast period, the sector is attracting increasing investments. This growth is expected to enhance the availability, accessibility, and demand for personalized medicines, paving the way for more tailored and effective treatments. As genetic innovations continue to evolve, the integration of these technologies into personalized medicine is set to revolutionize healthcare delivery, further accelerating market expansion.

Restraints in the Global Personalized Medicine Market

One of the key restraints for the global Personalized Medicines Market is the slow adoption of new technologies within the healthcare industry. The sector is typically conservative in integrating advanced innovations like AI and genetic engineering, largely due to stringent regulations. Regulatory bodies impose strict guidelines on the use of these technologies in healthcare applications, and authorities are often hesitant to approve their widespread adoption until they are fully confident in their safety and effectiveness. This cautious approach significantly delays the implementation of cutting-edge technologies in personalized medicine, hindering market growth and innovation in the field.

Market Trends of the Global Personalized Medicine Market

A significant trend in the global Personalized Medicines Market is the increase in healthcare budgets across both developed and developing economies, a shift that has gained momentum in the post-pandemic era. While stagnant healthcare budgets had been a concern for many years, governments have notably boosted funding for healthcare, which is directly fueling research and development (R&D) in alternative treatments and personalized medicines. This rise in healthcare expenditure is improving access to personalized medicine for patients who require tailored treatments and can afford them, thereby driving market growth and expanding patient access to innovative therapeutic options.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Value Chain Analysis
Patent Analysis
Case Study Analysis
Technology Analysis

Personalized Medicines Market by Product

Market Overview
Personalized Medicine Testing
- Genetic Testing
- DTC Testing
- Others
Personalized Medicine Therapeutics
- Pharmaceuticals
- Medical Devices
- Others
Personalized Medical Care
- Telemedicine
- Health Information Technology
Personalized Nutrition & Wellness
- Retail Nutrition
- Complementary & Alternative Medicine

Personalized Medicines Market by Application

Market Overview
Oncology
Neurology
Cardiology
Antiviral
Psychiatry
Immunology
Others

Personalized Medicines Market by End Users

Market Overview
Hospitals And Clinical Care
Diagnostic Companies and Testing Facilities
Academic Research Institutes and Research Laboratories
Contract Research Organizations
Bio And Health Informatics Companies
Others

Personalized Medicines Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EMD Serono, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MDxHealth SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Freenome Holdings, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haplogen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Molecular Partners AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SOPHiA GENETICS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantHealth, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celerion (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments